Recent FDA Approval of Immunotherapeutic Drugs Sparks Interest in Cancer Immunotherapy Treatments

Jan. 9, 2012 - PRLog -- PHILADELPHIA, PA  – Pharma IQ, a division of IQPC, announces the Cancer Immunotherapy Summit, being held February 27 - 29, 2012, at Metro Meeting Centers, Boston, MA.  Providing networking opportunities between top researchers in the field and industry innovators blazing the trail towards successful and sustained commercialization, the Summit explores the research and development of immunotherapeutics.

Approximately one out of every four deaths in 2010 can be attributed to some form of cancer. Between synthetic vaccines, immune modulators, immunotherapy antibodies and cell based investigational agents, the cancer immunotherapy field has a forecasted market potential of over $3 billion by 2015. Additionally, recent approval by the FDA of two immunotherapeutic drugs has sparked new interest in these technologies; there are already an estimated 150 potential products being studied, many of which are currently undergoing Phase II and Phase III clinical trials.

As technologies advance and new treatment mechanisms are investigated, the anticancer immunotherapy field may offer a new era of cancer treatment not seen ever before.  One emerging technology utilizes a modulated immune response mediated by T helper cells. In a recent interview, Eric von Hofe, Ph.D. President of Antigen Express, Inc. gave insights into this new advancement in immunotherapy and their studies investigating the efficacy and safety of these technology platforms.  The interview is available here in full:
http://www.cancerimmunotherapyevent.com/redForms.aspx?id=...

Featuring speakers from Advaxis, Inc., The Wistar Institute, Immunocellular Theraputics Ltd., National Cancer Institute, NIC and more, IQPC’s Cancer Immunotherapy Summit features the latest updates from industry innovators blazing the trail towards successful and sustained commercialization. Topics include:

• Approval processes and pitfalls within clinical trials
• Looking beyond the science and developing a sound business plan
• Learning from others who have successfully completed pre-clinical studies
• Investigating opportunities with using a combination of therapies
• FDA response in the field and gaining the support of industry gatekeepers
• Looking at development in both the non-profit and commercial setting

For more information on the Cancer Immunotherapy Summit, please visit http://www.cancerimmunotherapyevent.com or contact Taryn Soltysiak, Marketing Manager at Taryn.Soltysiak@iqpc.com.

# # #

IQPC (www.iqpc.com) provides business executives with tailored practical conferences, large-scale events, topical seminars and in-house training programs. Producing over 1,500 events annually around the world, IQPC continues to grow and has offices in cities across six continents including: Berlin, Dubai, London, New York, Sao Paulo, Singapore, Sydney, and Toronto.